Physician profile
Robert Wilson
NPI 1750390068
$231.17
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.32 · 2020: $58.57 · 2021: $115.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $78.57 | 2019-2021 | |
| Abbvie INC. | $26.91 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.31 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.37 | 2019 | |
| Amgen INC. | $18.70 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.08 | 2019 | |
| Lilly USA, LLC | $12.99 | 2021 | |
| Eisai INC. | $12.46 | 2021 | |
| Allergan, INC. | $12.06 | 2019 | |
| Esperion Therapeutics, INC. | $11.72 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.